Brief: Impel Neuropharma Reports Q4 Non-GAAP Loss Per Share $1.07

IPI Legacy Liquidation Co

24/03/2022 12:33

March 24 (Reuters) - Impel Neuropharma Inc  IMPL.O :
    * IMPEL NEUROPHARMA ANNOUNCES FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
    * Q4 NON-GAAP LOSS PER SHARE $1.07
    * IMPEL NEUROPHARMA - CO PROJECTS THAT TRUDHESA WILL DELIVER
PRESCRIPTIONS WITHIN RANGE OF 70,000 - 85,000 FOR FY 2022
    * BELIEVES, BASED ON ITS CURRENT OPERATING PLAN, THAT IT HAS
SUFFICIENT CAPITAL TO FUND OPERATIONS INTO 2024

Source text for Eikon:  ID:nGNXlQyfy 
Further company coverage:  IMPL.O 

 ((Reuters.Briefs@thomsonreuters.com;))